Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Retained Earnings: 2010-2024

Historic Retained Earnings for Cytokinetics (CYTK) over the last 14 years, with Dec 2024 value amounting to -$2.7 billion.

  • Cytokinetics' Retained Earnings fell 27.06% to -$3.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.3 billion, marking a year-over-year decrease of 27.06%. This contributed to the annual value of -$2.7 billion for FY2024, which is 27.91% down from last year.
  • Cytokinetics' Retained Earnings amounted to -$2.7 billion in FY2024, which was down 27.91% from -$2.1 billion recorded in FY2023.
  • Over the past 5 years, Cytokinetics' Retained Earnings peaked at -$992.3 million during FY2020, and registered a low of -$2.7 billion during FY2024.
  • Moreover, its 3-year median value for Retained Earnings was -$2.1 billion (2023), whereas its average is -$2.1 billion.
  • Data for Cytokinetics' Retained Earnings shows a maximum YoY crashed of 33.18% (in 2023) over the last 5 years.
  • Cytokinetics' Retained Earnings (Yearly) stood at -$992.3 million in 2020, then decreased by 21.70% to -$1.2 billion in 2021, then crashed by 31.33% to -$1.6 billion in 2022, then slumped by 33.18% to -$2.1 billion in 2023, then decreased by 27.91% to -$2.7 billion in 2024.